IGF-IR, MET, ERBB1/2, ERBB3, PDGFRa, AXL and FGFR1 have all been implicated in MEK-inhibitor resistance in KRAS-mutated tumors depending on the anatomical tumor type or specific cell line that was examined [92,97,104,105] (Figure 3). The gene discussed is KRAS; the disease is neoplasm.